Seattle Genetics Announces Data from Investigator Trial of ADCETRIS(TM) in ... 
MarketWatch (press release)
At the T-Cell Lymphoma Forum in January 2012, interim data were presented from a phase II investigator-sponsored trial in CD30-positive CTCL patients, including lymphomatoid papulosis, primary cutaneous anaplastic large cell lymphoma (pcALCL) or MF.
Seattle Genetics Announces Data from Investigator Trial of ADCETRIS? in ... Genetic Engineering News (press release)
Seattle Genetics: 75% Partial Remission From Adcetris Trial Wall Street Journal
Millennium starts Phase 3 cancer trial with Seattle Genetics Boston Business Journal
GenomeWeb  -Drug Store News 
all 24 news articles » 

Millennium and Seattle Genetics Initiate Global Phase 3 Trial of ADCETRIS(TM ... 
MarketWatch (press release)
... today announced the initiation of an international pivotal phase 3 clinical trial evaluating ADCETRIS (brentuximab vedotin) in patients with CD30-expressing cutaneous T-cell lymphoma (CTCL) who received at least one prior systemic therapy.
Seattle Genetics Reports First Quarter 2012 Financial Results PharmaLive.com (press release)

all 26 news articles » 

Seattle Genetics Announces Data from Investigator Trial of ADCETRIS? in ... 
EON: Enhanced Online News (press release)
(EON: Enhanced Online News)--Seattle Genetics, Inc. (Nasdaq: SGEN) today announced that interim results from an investigator-sponsored phase II clinical trial of ADCETRIS (brentuximab vedotin) in patients with relapsed cutaneous T-cell lymphoma (CTCL) ...
Millennium, Seattle Genetics commence Phase III CTCL trial Pharmaceutical Business Review

all 11 news articles » 

Cyclacel to Report New Sapacitabine Clinical Data at the American Society of ... 
MarketWatch (press release)
... registration-directed, Phase 3 trial in elderly patients with newly diagnosed acute myeloid leukemia (AML), Phase 2 trials in patients with hematological malignancies, including myelodysplastic syndromes (MDS), cutaneous T-cell lymphoma (CTCL), ...

and more » 

Cyclacel Announces Completion of Enrollment in Investigator-Initiated, Phase 2 ... 
MarketWatch (press release)
... a registration-directed, Phase 3 trial in elderly patients with newly diagnosed acute myeloid leukemia (AML), Phase 2 trials in patients with hematological malignancies, including myelodysplastic syndromes (MDS), cutaneous T-cell lymphoma (CTCL), ...

and more » 

Skin Cancer Awareness: With Melanoma Rising Among Young Adults, New Treatments ... 
Newswise (press release)
Currently, three Phase II clinical trials to test OncoSec's technology are underway, not only in metastatic melanoma but also in Merkel cell carcinoma and cutaneous T-cell lymphoma. There are currently few, if any, treatment options for these cancers.

and more » 

Warden's colleagues go from roof to donor drive 
Kennebec Journal
Gregory Sanborn, who has cutaneous T-cell lymphoma and needs a matching donor transplant to survive. Tim Peabody, former colonel of the Maine Warden Service, who is organizing the event, said that Sanborn has responded to calls for help for 23 years ...
Colleagues give cancer-stricken warden new roof Press Herald

all 4 news articles » 

Expanded Treatment Options for Leukemia/Lymphoma 
Cancer Network
Histone deacetylase inhibitors are newer agents used for cutaneous T-cell lymphoma. These novel agents may have mild side effects in general, but patients should also be monitored for severe effects, such as pulmonary embolism and myelosuppression.

and more » 

Allos Therapeutics Announces Outcome of Request for Re-examination of CHMP ... 
EON: Enhanced Online News (press release)
We also remain fully committed to advancing the FOLOTYN development program in hematologic malignancies, including first-line PTCL and relapsed or refractory cutaneous T-cell lymphoma.? In May 2011, Allos entered into a strategic collaboration ...

and more » 

Finding a stem cell donor is warden Gregory Sanborn's 'only hope' for fighting ... 
Lewiston Sun Journal
The cutaneous T-cell lymphoma that is ravaging his body wins. ?Basically, it's my only hope,? Sanborn said of the stem-cell transplant he has been left to hope for. ?If it works, I'll be cured. And if it doesn't, I won't be.? Sanborn, a 46-year-old ...

and more »